Navigation Links
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Date:6/3/2009

biparsciences.com.

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applica
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
2. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
3. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
4. Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis
5. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
6. Premier Research Announces Milestone Investigational New Drug Application
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
9. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
10. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
11. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Mass. , July 28, 2015  Insulet Corporation ... pump technology with its OmniPod ® Insulin Management ... has been appointed to Insulet,s Board of Directors. ... top-tier healthcare experience to the Insulet Board. She currently ... the Joslin Diabetes Center, the world,s largest diabetes research ...
(Date:7/28/2015)... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) ... financial results after the market closes on Tuesday, August ... will be held on Tuesday, August 4, 2015, at ... To participate in the call, please dial 877-303-1298 ... rebroadcast of the teleconference will be available for one ...
(Date:7/28/2015)... /PRNewswire-USNewswire/ -- Kentucky,s ... after a 2012 law required providers to check a ... yet more evidence that Californians need the same protections, ... Kentucky,s prescription drug abuse legislation took ... 52 percent; opioid prescriptions to doctor-shopping individuals dropped by ...
Breaking Medicine Technology:Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 2Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 3Cumberland Pharmaceuticals To Announce Second Quarter 2015 Financial Results 2Study Shows Requiring Prescription Drug Database Use Before Prescribing Powerful, Addictive Medications Critical In Ending Growing Epidemic, says Consumer Watchdog 2
... LEUVEN, Belgium, September 29 , - Results ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused ... and cancer,announces positive results from its MITI IV ... efficacy of microplasmin when administered,intravenously to acute stroke ...
... Dikembe Mutombo Foundation to improve healthcare,system in the ... Sept. 25 The Clinton Global,Initiative recognized BD ... a,leading global medical technology company, for its commitment ... system monitoring and,healthcare worker safety at the Biamba ...
Cached Medicine Technology:ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 2ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 3ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 4Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 2Clinton Global Initiative Announces BD's Commitment to Biamba Marie Mutombo Hospital 3
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent Marketing, a vertically ... invention that makes shelling eggs an exact science. , “The global kitchen appliances ... and Creative Director of World Patent Marketing. “With a growth rate of 6.4%, ...
(Date:7/28/2015)... ... , ... The Denver Foundation and Blair-Caldwell African American Research ... photographic and narrative exploration of African American giving, which runs August 1-31 at ... is one of only ten cities to host “The Soul of Philanthropy Reframed ...
(Date:7/28/2015)... ... 28, 2015 , ... Autism is the fastest growing serious ... with the disorder. For these families, identifying and paying for the help they ... That’s where Talk About Curing Autism (TACA), a national non-profit organization dedicated to ...
(Date:7/28/2015)... ... July 16, 2015 (PRWEB) July 28, 2015 , ... Nations ... Health insurance quotes to its clients, recently announced the launch of Commercial, Auto ... suits their specific needs. , Liability automobile insurance policies are one popular ...
(Date:7/28/2015)... FL (PRWEB) , ... July 28, 2015 , ... Dr. ... diseases. , The talk took place from noon to 1 p.m. Tuesday, June 23, ... Panama City, Fla. , Dr. Ahmad is board-certified in colorectal surgery and has ...
Breaking Medicine News(10 mins):Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 3Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 4Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 5Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2
... on findings of a recent study researchers say Lipid-lowering drugs ... // or at a follow-up appointment with a doctor. ... is started during a hospital stay vs. in an outpatient ... the United States and Canada were involved in the study, ...
... known scientist and accomplished businessman of the U.S. holding ... to set up a high end rapid //diagnostic centre ... be a marketing, selling and research company. ... BioAsia 2004 conference Bangalore on February 28, he said ...
... and benefits of using CT scanning for young children ... than 3,000 men who received radiation therapy before 18 ... at age 18 years or 19 years. Researchers also ... ,Results of the study showed boys who received increasing ...
... study assessing the use of hormone replacement therapy among breast ... an unacceptably high rate of recurring or new cancers. ... women are surviving the disease and therefore subject to the ... to involve around 1,300 women over five years. After the ...
... of osteoporosis. Such a break can lead to acute and ... to a recent study , it was found that the ... effective in reducing the risk for a vertebral fracture, according ... can reduce the risk of breaking a bone in the ...
... technology may help people suffering from paralysis reprogram their ... to findings of a recent study . ,Functional ... during motor activities and allow patients to redirect motor ... taking over for the damaged ones. But until now, ...
Cached Medicine News:
The Stereomicroscope Stemi 2000 meets your demands in two respects. On the one hand it offers the low-price advantage common with Greenough-type instruments, on the other hand it features superior pe...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
The SZX9 is one of the top research stereo microscopes in the Olympus line. It has the largest zoom range of any of our stereo microscopes....
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
Medicine Products: